Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery

被引：245

作者：

Brough, Chris ^{[1
,2
]}

Williams, R. O., III ^{[1
]}

机构：

[1] Univ Texas Austin, Coll Pharm, Div Pharmaceut, Austin, TX 78712 USA

[2] DisperSol Technol LLC, Georgetown, TX 78626 USA

来源：

INTERNATIONAL JOURNAL OF PHARMACEUTICS | 2013年 / 453卷 / 01期

关键词：

Poorly water-soluble drugs; Amorphous solid dispersions; Nanoparticles; Nano-crystal; BIOPHARMACEUTICS CLASSIFICATION-SYSTEM; ORAL BIOAVAILABILITY; MELT EXTRUSION; PHARMACOKINETIC VARIABILITY; ZIPRASIDONE FORMULATIONS; PART I; SOLUBILITY; ITRACONAZOLE; ABSORPTION; STABILIZATION;

D O I：

10.1016/j.ijpharm.2013.05.061

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Poor water-solubility is a common characteristic of drug candidates in pharmaceutical development pipelines today. Various processes have been developed to increase the solubility, dissolution rate and bioavailability of these active ingredients belonging to BCS II and IV classifications. Over the last decade, nano-crystal delivery forms and amorphous solid dispersions have become well established in commercially available products and industry literature. This article is a comparative analysis of these two methodologies primarily for orally delivered medicaments. The thermodynamic and kinetic theories relative to these technologies are presented along with marketed product evaluations and a survey of commercial relevant scientific literature. (c) 2013 Elsevier B.V. All rights reserved.

引用

页码：157 / 166

页数：10

共 91 条

[1]

[Anonymous], 2010, NY TIMES

[2] Nanosuspension technology and its applications in drug delivery [J].

Arunkumar, N. ;

Deecaraman, M. ;

Rani, C. .

ASIAN JOURNAL OF PHARMACEUTICS, 2009, 3 (03) :168-173

[3] Ritonavir: An extraordinary example of conformational polymorphism [J].

Bauer, J ;

Spanton, S ;

Henry, R ;

Quick, J ;

Dziki, W ;

Porter, W ;

Morris, J .

PHARMACEUTICAL RESEARCH, 2001, 18 (06) :859-866

[4] Supersaturating Drug Delivery Systems: The Answer to Solubility-Limited Oral Bioavailability? [J].

Brouwers, Joachim ;

Brewster, Marcus E. ;

Augustijns, Patrick .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (08) :2549-2572

[5]

Brunner E, 1904, Z PHYS CHEM-STOCH VE, V47, P56

[6] Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development [J].

Chemburkar, SR ;

Bauer, J ;

Deming, K ;

Spiwek, H ;

Patel, K ;

Morris, J ;

Henry, R ;

Spanton, S ;

Dziki, W ;

Porter, W ;

Quick, J ;

Bauer, P ;

Donaubauer, J ;

Narayanan, BA ;

Soldani, M ;

Riley, D ;

McFarland, K .

ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2000, 4 (05) :413-417

[7] Role of polymeric stabilizers for drug nanocrystal dispersions [J].

Choi, JY ;

Yoo, JY ;

Kwak, HS ;

Nam, BU ;

Lee, J .

CURRENT APPLIED PHYSICS, 2005, 5 (05) :472-474

[8] Stabilization of low glass transition temperature indomethacin formulations: Impact of polymer-type and its concentration [J].

Chokshi, Rina J. ;

Shah, Navnit H. ;

Sandhu, Harpreet K. ;

Malick, Ahmad W. ;

Zia, Hossein .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (06) :2286-2298

[9] Nanoparticles: A personal experience for formulating poorly water soluble drugs [J].

Cooper, Eugene R. .

JOURNAL OF CONTROLLED RELEASE, 2010, 141 (03) :300-302

[10] Pharmaceutical applications of hot-melt extrusion: Part I [J].

Crowley, Michael M. ;

Zhang, Feng ;

Repka, Michael A. ;

Thumma, Sridhar ;

Upadhye, Sampada B. ;

Battu, Sunil Kumar ;

McGinity, James W. ;

Martin, Charles .

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2007, 33 (09) :909-926

← 1 2 3 4 5 6 7 8 9 10 →